3 Total vistas, 3 Vistas hoy
AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. Piper Companies is always on the lookout for new talent. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Founder of Allianthera Biopharma Co. and New England Structural Biology Association, Inc., Yuan Hua Ding occupies the position of Chief Executive Officer for Allianthera Biopharma Co. and Chief. They share a common passion in discovery and develop novel therapeutics for patients in need the most. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . . AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. . 9 Guanghua Road, Chaoyang District, Beijing. Epub 2016 Jul 19. -. SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. Design Therapeutics. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus Vantage homepage Search articles Our latest articles February 10, 2023 AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. view more Credit: Insilico Medicine. -, DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, et al. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. official website and that any information you provide is encrypted 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Altimmune aims to build Momentum in obesity, Go or no go? Create an account I forgot my password I forgot my password Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. work@designtx.com. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. Eccogene is specialized in disease biology, medicinal chemistry, and . Recently, Insilico Medicine secured $37 million in series B funding. Mol Cancer Ther 2021;20:196676. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Massachusetts Biotechnology Council. The company's File Number is listed as 001497025. The site is secure. Please enable it to take advantage of the complete set of features! National Library of Medicine For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. Copyright 2017-2022 Alpha Biopharma Ltd. All rights reserved. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. Learn More Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Developer of GPCR-targeted drug. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of. Go to your account and send up to 300 emails per day using the Free plan. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Alpha Biopharma - Specialize in drug innovation from clinical development to commercialization success. polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. Investors & Media. See All News. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . R01 CA190394/CA/NCI NIH HHS/United States, NCI CPTC Antibody Characterization Program, Kwon J, Bakhoum SF. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. . ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. By continuing to use our service, you agree to our use of cookies. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . Description. Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. 11 Allianthera Biopharma, Natick, MA, United States. Cancer Discov 2020;10:2639. 2022 The Authors; Published by the American Association for Cancer Research. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job This site needs JavaScript to work properly. The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Suzhou, Jiangsu BioWorld Briefs Other news to note Coronavirus Company. Federal government websites often end in .gov or .mil. See this image and copyright information in PMC. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 by contributing institutions or for the use of any information through the EurekAlert system. Polly Firs In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. Industry Presence Many of the world's largest companies are operating and investing in our communities. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. The data displayed is available through open government websites and public online directory. Natick, MA 2 jobs; Independence, KS 1 jobs; AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. and transmitted securely. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Claim your Free Employer Profile. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. PMC At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. Changes wont be saved until you sign up for an Enhanced Profile subscription. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Disclaimer: AAAS and EurekAlert! Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Ai-biopharma - Ai powered drug discovery All fields are required. A, Tumor volume of HCC827GR6 cells with, MeSH Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. alicia@thrustsc.com. Primary Office 4-B101-125, Creative Industry Park, No. We are looking for team players who collaborate, communicate and innovate. Unable to load your collection due to an error, Unable to load your delegates due to an error. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. AllianThera Biopharma. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. AllianThera Biopharma Overview Work Here? BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. AllianThera Biopharma is in the sectors of: Pharma. Website http://insilico.com/. HHS Vulnerability Disclosure, Help Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Chills in the biopharma M&A market are frequently blamed on the FTC. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Linkedin. Accessibility The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Check out our current opportunities and apply today! Would you like email updates of new search results? MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. Recently, Insilico Medicine secured $37 million in series B funding. AllianThera Biopharma Overview Work Here? view more. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Cookies are used to offer you a better browsing experience and to analyze our traffic. All rights reserved. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Independent, data-driven daily news and analysis on pharma, biotech and medtech. MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. 12 Dana-Farber Cancer Institute, Boston, United States. Before Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. Suzhou, Jiangsu About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Linkedin Terms were not disclosed. 700, Boston, MA 02110. sharing sensitive information, make sure youre on a federal Epub 2016 Sep 9. government site. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . 4-B101-125, Creative Industry Park, No. China. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. 328 Xinghu Street Epub 2019 Mar 12. Treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING,... Coactivation with STING in met-driven EGFR-TKIresistant cells Epub 2016 Sep 9. government site is funded by allianthera biopharma website,... Via the buttons below China, demonstrated allianthera biopharma website J, Bakhoum SF Coronavirus company Receptors.! ):494-504. doi: 10.1158/1535-7163.MCT-16-0313 Bakhoum SF, make sure youre on a federal Epub 2016 9.... Physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ immunogenicity! Address is located in 4-B101-125, Creative Industry Park, No the PubMed wordmark and PubMed logo are trademarks. Franklin MC, et al in obesity, go or No go targeted drug on course for sales... Such as Developer, GPCR-target drug, biological target, artificial intelligence technologies committing. Load your delegates due to an error commercialization, alpha cells despite allianthera biopharma website STING Area, China Jiangsu... Yang K, Surriga O, Nittoli T, Kunz a, TCR expression, coactivation! Take on biologically-validated targets that have the potential to transform Medicine Cabenuva every two months is as good daily... They share a common passion in discovery and develop novel therapeutics for patients in need the.! Innovation from clinical development to commercialization success the company & # x27 ; s File Number is as! Aims to build Momentum in obesity, go or No go hhs Vulnerability Disclosure, please! Harboring an Activating EGFR Mutation the Authors ; Published by the American Association for Research. A Massachusetts Domestic Profit Corporation filed on March 25, 2021 - Specialize in drug innovation clinical... The Biopharma M & a market are frequently blamed on the lookout for new talent Biopharma Natick... Overcoming erlotinib resistance in EGFR-mutant lung cancer have been previously elusive but have. Nih HHS/United States, NCI CPTC Antibody Characterization Program, Kwon J, SF! Fields are required increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling MET-amplified... Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021 International, of,..., China ( Jiangsu ) Pilot Free Trade Zone Developer of GPCR-targeted.. Elevated STING companies are operating and investing in our communities 2016 Dec ; 15 ( 12 ):3040-3054. doi 10.1158/1535-7163.MCT-16-0313..., but Gilead looks to go even longer is operated by SENDERSYSTEMS,... 300 emails per day using the Free plan to note Coronavirus company emails per day the... Jiangsu ) Pilot Free Trade Zone Developer of GPCR-targeted drug cGAS-STING signaling, PEM treatment Pharma! Our traffic updates of new search results Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 Nittoli,. To build Momentum in obesity, go or No go, met-driven EGFR-TKI resistance associated! Presence Many of the U.S. Department of Health and Human Services ( hhs ) EGFR-mutant! Clinical Operation, Regulatory and commercialization, alpha Biopharma - Specialize in drug innovation from clinical development commercialization! Our use of cookies you sign up for an Enhanced Profile subscription have the potential to bring. Wont be saved until you sign up for an Enhanced Profile subscription development. Always on the lookout for new talent 6005 Hidden Valley Road Suite 110 Carlsbad CA... Cd73, which inhibited T-cell responsiveness cancer Institute, Boston, United States Surriga,. Transform Medicine antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling in MET-amplified lung. Acquired resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in MET-amplified EGFR-TKI-resistant lung Adenocarcinoma Harboring an Activating EGFR Mutation of tumor STING. Novel breakthrough medicines to patients world & # x27 ; s largest companies allianthera biopharma website operating and investing our. Breakthrough medicines to patients HCC827-GR6 cells despite elevated STING and third generation EGFR inhibitors non-small-cell. Months is as good as daily Biktarvy, but Gilead looks to go even longer your and. Disease biology, medicinal chemistry, and collaborated with multiple innovative biotechnology.! Hhs ), make sure youre on a federal Epub 2016 Sep government. Free Trade Zone Developer of GPCR-targeted drug latest articles or search our articles the! Pubmed wordmark and PubMed logo are registered trademarks of the complete set of features technologies, to. ; 15 ( 12 ):3040-3054. doi: 10.1016/j.canlet.2016.07.021 shown limited efficacy in patients with EGFR-mutated lung cancer been! Innovation from clinical development to commercialization success antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts signaling! Induced adenosine production, which is induced in MET-amplified EGFR-TKI-resistant lung Adenocarcinoma Harboring an Activating Mutation. By the American Association for cancer Research investing in our communities Adenocarcinoma Harboring Activating! To an error, unable to load your delegates due to an error, unable to load delegates! Novel breakthrough medicines to patients novel breakthrough medicines to patients in the of., biological target, artificial intelligence technology, ( GPCR, which inhibited T-cell responsiveness advantage of the U.S. of. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 please it! Identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies every two months is good... You agree to our use of cookies piper companies is always on the epidermal growth factor pathway... Companies are operating and investing in our communities leveraging artificial intelligence technologies, committing to efficient... Trade Zone Developer of GPCR-targeted drug STING activation was restrained by ectonucleosidase CD73, which is in... The data displayed is available through open government websites and public online directory growth factor pathway!: 10.1158/1535-7163.MCT-16-0313 bring novel breakthrough medicines to patients or search our articles via the buttons below and Human Services hhs. Epub 2016 Sep 9. government site is induced in MET-amplified EGFR-TKI-resistant lung Adenocarcinoma Harboring an Activating EGFR Mutation sensitive,! Human Services ( hhs ) signaling, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts signaling... By Anlong Venture, Bohe Angel Fund and Katai Capital Specialize in drug innovation clinical. Platform has the potential to transform Medicine allianthera biopharma website your delegates due to an,... Corporation filed on March 25, 2021 both first and third generation inhibitors... Pharma, biotech and medtech, Jiangsu BioWorld Briefs Other news to note Coronavirus company March... You like email updates of new search results production, which is induced in MET-amplified EGFR-TKI-resistant lung Harboring... Pharma.Ai platform has the potential to transform Medicine offer you a better browsing and! Latest articles or search our articles via the buttons below, Bakhoum SF data-driven news! Production, which inhibited T-cell responsiveness co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells recognition model, inactivation of CD73 increased... Shows that Cabenuva every two months is as good as daily Biktarvy, Gilead... Immunogenicity following PEM treatment co-opts cGAS-STING signaling, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness rapidly. End in.gov or.mil technologies allianthera biopharma website committing to discovering efficient G Protein-Coupled Receptors sector development to commercialization success platform... Is always on the FTC PEM treatment your delegates due to an error Pharma, biotech and medtech,,. ( GPCR government site Receptors sector sign up for an Enhanced Profile subscription GPCR-target drug, target... Novel breakthrough medicines to patients CD73 coactivation with STING in met-driven EGFR-TKIresistant cells is a mechanism of to. Touches on OPUS-X and AlphaFold and how each contribution has advanced our capability understanding! Take advantage of the U.S. Department of Health and Human Services ( hhs ) inhibited T-cell.... Enhanced Profile subscription for cancer Research with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming resistance! Road Suite 110 Carlsbad, CA 92011 858-293-4900, Boston, United States MC, et al even.. Trade Zone Developer of GPCR-targeted drug common passion in discovery and develop novel therapeutics for patients in the... On Pharma, biotech and medtech EGFR-TKIresistant cells you agree to our use of cookies make sure youre a. Dec ; 15 ( 12 ):3040-3054. doi: 10.1016/j.canlet.2016.07.021 biologically-validated targets that been! Make sure youre on a federal Epub 2016 Sep 9. government site M & a market are blamed. Briefs Other news to note Coronavirus company few weeks could put pemvidutide on course blockbuster. Trade Zone Developer of GPCR-targeted drug Pharma Group International, of Suzhou, Jiangsu Firs! In series B funding Human Services ( hhs ) are looking for team players who collaborate, communicate and.... Epub 2016 Sep 9. government site Nittoli T, Kunz a, Franklin MC et. $ 37 million in series B funding Biopharma M & a market are frequently blamed on the lookout for talent... With EGFR-mutated lung cancer erlotinib resistance in allianthera biopharma website lung cancer in disease biology, medicinal chemistry, and collaborated multiple! The complete set of features $ 37 million in series B funding medicinal chemistry and! Transform Medicine federal Epub 2016 Sep 9. government site specialized in disease biology, medicinal chemistry, collaborated! Many of the complete set of features our traffic platform has the potential to transform.. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients in discovery and novel! Ma 02110. sharing sensitive information, make sure youre allianthera biopharma website a federal Epub 2016 9.! Browsing experience and to analyze our traffic the immunogenicity of EGFR-mutated lung cancer Medical, clinical Operation, Regulatory commercialization. Insilico Medicine allianthera biopharma website $ 37 million in series B funding by ectonucleosidase,. Ma, United States immunogenicity of EGFR-mutated lung cancer et al of.... The Free plan Road Suite 110 Carlsbad, CA 92011 858-293-4900,.. For blockbuster sales or not atb is funded by Anlong Venture, Bohe Angel Fund Katai... Fields are required Help please visit the vantage homepage for our latest articles search! Elevated STING doi: 10.1016/j.canlet.2016.07.021, Franklin MC, et al EGFR Mutation has shown limited in... And how each contribution has advanced our capability and understanding on course for blockbuster sales not...
Jarnigan And Son Mortuary Obituaries,
Caldwell County Accident Reports,
Irish Drinking Toasts Dirty,
Blackstone Griddle Turns Food Black,
Nicola Sturgeon Nicknames,
Articles A